Shandong Xinhua Pharmaceutical Company Limited Class H (XIN) AI Stock Analysis

Shandong Xinhua Pharmaceutical Company Limited Class H

(Frankfurt:XIN)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Manageable leverageThe company remains profitable while debt-to-equity has generally stayed near 0.24–0.34, indicating leverage is manageable. A growing equity base provides financial capacity to sustain operations and pursue investment through the next several quarters.

Negative Factors

Revenue slowdownThe TTM revenue pullback interrupts the company’s prior multi-year growth pattern and signals weaker recent demand or business momentum. If sustained, slower sales would reduce operating leverage and make it harder to rebuild earnings growth over the next several quarters.

Shandong Xinhua Pharmaceutical Company Limited Class H (XIN) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 8.06B
Dividend Yield: 3.18%
Average Volume (3M): ―
Price to Earnings (P/E): 37.2
Beta (1Y): 0.16
Revenue Growth: -5.81%
EPS Growth: -41.87%
Country: Germany
Employees: 7,240
Sector: Healthcare
Sector Strength: 51
Industry: Medical - Pharmaceuticals

Shandong Xinhua Pharmaceutical Company Limited Class H Business Overview & Revenue Model

Company Description

Shandong Xinhua Pharmaceutical Company Limited develops, manufactures, and sells bulk pharmaceuticals, preparations, and chemical products in the People's Republic of China, the Americas, Europe, and internationally. The company offers antipyretic an...

Shandong Xinhua Pharmaceutical Company Limited Class H Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:XIN against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
HK:1681	87Outperform	HKD 12.54B	9.36	25.10%	5.11%	15.05%	20.58%
HK:1513	77Outperform	HKD 26.72B	16.30	11.32%	6.71%	-9.56%	-23.22%
HK:3320	68Neutral	HKD 29.12B	6.18	7.92%	5.17%	7.94%	52.83%
HK:0874	57Neutral	HKD 35.32B	14.74	5.57%	6.71%	6.00%	-23.05%
HK:0460	56Neutral	HKD 6.76B	18.38	5.03%	1.50%	29.68%	―
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

* Healthcare Sector Average

Performance Comparison

DE:XIN and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:XIN	Shandong Xinhua Pharmaceutical Company Limited Class H	0.58	-0.14	-19.67%
HK:0874	Guangzhou Baiyunshan Pharmaceutical Holdings Company Class H	12.86	-5.10	-28.41%
HK:1513	Livzon Pharmaceutical Group Class H	23.18	-5.02	-17.81%
HK:0460	Sihuan Pharmaceutical Holdings Group	0.72	-0.75	-50.71%
HK:3320	China Resources Pharmaceutical Group Ltd.	4.63	-0.11	-2.26%
HK:1681	Consun Pharmaceutical Group Ltd.	15.25	1.00	7.00%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Shandong Xinhua Pharmaceutical Company Limited Class H AI Stock Analysis